Background: Parkinson's disease (PD) is characterized by brain metabolic networks, specifically associated with motor and cognitive manifestations. Few studies have investigated network changes in cerebral hemispheres ipsilateral and contralateral to the clinically more affected body side.

Objective: We examined hemispheric network abnormalities and their relationship to striatal dopaminergic deficits in PD patients at different stages.

Methods: 45 PD patients underwent dual-tracer positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) and 18F-fluorodopa (FDOPA) in a high-resolution PET scanner. In all patients, we computed expression levels for the PD-related motor/cognition metabolic patterns (PDRP/PDCP) as well as putamen/caudate FDOPA uptake values in both hemispheres. Resulting hemispheric measures in the PD group were compared with corresponding healthy control values and assessed across disease stages.

Results: Hemispheric PDRP and PDCP expression was significantly elevated contralateral and ipsilateral to the more affected body side in patients with unilateral symptoms (H&Y 1: p < 0.01) and in patients with bilateral limb involvement (H&Y 2-3: p < 0.001; H&Y 4: p < 0.003). Elevations in pattern expression were symmetrical at all disease stages. By contrast, FDOPA uptake in the caudate and putamen was reduced bilaterally (p < 0.002), with lower values on both sides at more advanced disease stages. Hemispheric uptake was asymmetrical in both striatal regions, with lower contralateral values at all disease stages. The magnitude of hemispheric uptake asymmetry was smaller with more advanced disease, reflecting greater change ipsilaterally.

Conclusion: Symmetrical network expression in PD represents bilateral functional effects unrelated to nigrostriatal dopaminergic asymmetries.

Download full-text PDF

Source
http://dx.doi.org/10.3233/JPD-202117DOI Listing

Publication Analysis

Top Keywords

hemispheric network
8
parkinson's disease
8
hemispheric
4
network expression
4
expression parkinson's
4
disease relationship
4
relationship dopaminergic
4
dopaminergic asymmetries
4
asymmetries background
4
background parkinson's
4

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Brain Imaging and Analysis Center, Duke University Medical Center, Durham, NC, USA.

Background: Alzheimer's disease (AD) causes a steady degradation of connections inside the brain. The apolipoprotein E is a protein where one of its subtypes, APOE4, is a major genetic risk factor for developing late onset AD. Using a combination of tensor network PCA (TN-PCA) and bundle analysis, we sought to determine which specific connections differentiate APOE4 individuals relative to non-APOE4 carriers, and whether these changes increase with age.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Stanford University, Stanford, CA, USA.

Background: To maintain local dynamic stability (LDS), both cognitively and physically, without being interfered with by internal or external disturbance is important for functional independence but declines as ages. However, some older adults are capable of high dual-functional LDS. Understanding the brain differences between these older adults and their counterparts may help discover protective mechanisms for functional independence in old age.

View Article and Find Full Text PDF

Background: The common marmoset (Callithrix jacchus) is an important animal model in neuroscience and neurological diseases (e.g., Alzheimer's disease - AD), as they present primate-specific evolutionary features such as an expanded frontal cortex.

View Article and Find Full Text PDF

Background: Tau aggregates in Alzheimer's disease (AD) induce loss of synapses and neurons, leading to cognitive impairment. Predicting tau and neurodegeneration temporal evolution could be used for prognostication and for assessing results of therapeutic trials. Tau PET and MRI volumetry are reliable markers of disease stage, but cost and radiation protection considerations limit research measurement frequency, lowering the accuracy of disease progression modeling.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

Background: Glutamate is the main excitatory neurotransmitter in the brain, acting through ionotropic and metabotropic receptors, such as the neuronal metabotropic glutamate receptor 5 (mGluR5). The radiotracer [C]ABP688 binds allosterically to the mGluR5, providing a valuable tool to understand glutamatergic function. We have previously shown that neuronal [C]ABP688 binding is influenced by astrocyte activation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!